Dyslipidemia and nephrotic syndrome: Recent advances

Kronenberg, Florian

doi:10.1053/j.jrn.2004.10.003

Cited by 70 publications

(43 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the lipoprotein phenotypes in this condition vary among type Ⅱa (increased LDL), type Ⅱb (increased LDL and VLDL), and type Ⅳ (increased VLDL), depending on the degree of LPL suppression. HDL-C is reported to be unchanged or reduced in human nephrotic syndrome 38) . Reduction of plasma HDL-C may be explained to some extent by the loss of α-migrating lipoproteins into urine 39) .…”

Section: Meta-analysis Of Studies In the General Populations Worldwidementioning

confidence: 99%

“…This figure was developed by the authors based on the original paper by Yasuno et al 34) emia secondary to CKD can be discussed separately in proteinuria-dominant CKD and reduced GFR-dominant CKD (Table 4). Nephrotic syndrome is a representative condition for the first group of patients 38) . The hepatic production of very low density lipoprotein (VLDL) is elevated because of a nonspecific increase in protein secretion by the liver to compensate for hypoalbuminemia caused by massive loss of serum proteins into urine.…”

Section: Meta-analysis Of Studies In the General Populations Worldwidementioning

confidence: 99%

See 1 more Smart Citation

Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis

Shoji

Abe

Matsuo³

et al. 2012

JAT

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are at an increased risk not only for end-stage kidney disease (ESKD) but also for cardiovascular disease (CVD). In this review article, we summarize the current evidence of CKD as a high-risk condition for CVD based on reports from Japan and other countries to draw attention to the close clinical association between CKD and CVD. Several epidemiologic studies have shown that the presence of CKD and reduced renal function are independent predictors of CVD also in Japan. According to a post-hoc analysis of CASE-J, the power of CKD as a predictor of CVD is as strong as diabetes mellitus and a previous history of ischemic heart disease. CKD worsens classical risk factors including hypertension and dyslipidemia, and dyslipidemia is associated with increased thickness and stiffness of large arteries independent of major confounders. A post-hoc analysis of MEGA indicates that lipid-lowering therapy with statins reduces the risk of CVD, and that it appears to be more efficacious in patients with than without CKD. These reports from Japan and other countries suggest that CKD should be regarded as a high-risk condition comparable to diabetes mellitus, and that strict control of dyslipidemia would be beneficial in preventing CVD, at least early stages of CKD.

show abstract

Section: Meta-analysis Of Studies In the General Populations Worldwidementioning

confidence: 99%

Section: Meta-analysis Of Studies In the General Populations Worldwidementioning

confidence: 99%

Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis

Shoji

Abe

Matsuo³

et al. 2012

JAT

View full text Add to dashboard Cite

show abstract

“…These reports demonstrate that the existence of PAD increased risk of CVD observed in patients with CKD 8) . Regarding lipids, CKD is a representative cause of secondary hyperlipidemia; nephrotic syndrome 15) is often accompanied by hyper-LDL cholesterolemia, while chronic renal failure 16) is often accompanied by hypertriglyceridemia due to the accumulation of remnant lipoproteins or a high VLDL level and hypo-HDL cholesterolemia. The non HDL cholesterol (HDL-C) level, the sum of the levels of cholesterol in TG-rich lipoproteins and LDL, has been reported to be an independent factor associated with the carotid artery intima-media thickness (IMT) 17) and pulse wave velocity (PWV) 18) in CKD patients.…”

Section: Executive Summary Of the Japan Atherosclerosis Society (Jas)mentioning

confidence: 99%

Other High-Risk Conditions

Teramoto

Sasaki

Ishibashi

et al. 2013

JAT

View full text Add to dashboard Cite

“…It involves all lipoprotein classes, shows considerable variations depending on the stage of CKD [50,51] and is further modified by concurrent diseases such as diabetes [52] and nephrotic syndrome [53]. In addition, major qualitative compositional changes in lipoprotein particles, such as oxidation, glycation, carbamylation and formation of small dense LDL (sdLDL -see below) which render the particles more atherogenic, have been observed [54].…”

Section: Lipoprotein Metabolism In Hd Patients Suffering From Chronicmentioning

confidence: 99%